Search Results
Your search for ,WHo matches 20407 pages
Showing 3501 - 3550Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
YES Oklahoma Project Created to Improve Representation of Native Americans in Cancer Research
The National Cancer Institute of the National Institutes of Health (NIH) has awarded the University of Oklahoma (OU) an expected $2 million over 5 years to develop a program to improve representation of Oklahoma Native American students in biomedical and cancer research. “American Indian...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer: Use of Elacestrant in the Phase III EMERALD Trial
Endocrine therapy is the foundation of first-line therapy in most patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Many of these patients respond to endocrine therapy but eventually become resistant to it through both intrinsic and acquired resistance mechanisms....
Elacestrant Improves Progression-Free Survival vs Standard Endocrine Therapy in Previously Treated Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, of the Institut Curie, Paris and Saint Cloud, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor degrader elacestrant vs standard...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
Future Leaders Selected to Advance Gender Equality Through the Leadership Programme for Women in Oncology
The first 10 participants in the new Leadership Programme for Women in Oncology have been announced. The program, a joint endeavour from ASCO and City Cancer Challenge Foundation (C/Can), seeks to address the specific challenges and barriers faced by women leaders in oncology and strengthen the...
SIO-ASCO Guideline Proposes Evidence-Based Approaches to Pain Management Incorporating Integrative Medicine Interventions
The Society for Integrative Oncology (SIO) and ASCO have released a guideline that appraises the evidence to support incorporating integrative medicine approaches into managing pain in adults with cancer.1 The guideline builds upon existing ASCO guidelines on pain management, the growing body of...
For William L. Dahut, MD, a Career of Service in Oncology
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with William L. Dahut, MD, who is currently serving as Chief Scientific Officer for the American Cancer Society (ACS). In this role, Dr. Dahut manages all pieces of the organization’s discovery work,...
Richter Transformation Remains Challenging, but Better Treatments Are on the Horizon
Richter transformation, usually a diffuse large B-cell lymphoma developing in a person with CLL, remains a challenging entity, but novel regimens look promising, as described at the 2022 Pan Pacific Lymphoma Conference by Matthew S. Davids, MD, MMSc, Associate Professor of Medicine at Harvard...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
Expert Point of View: Natasha Leighl, MD
“Platinum-ineligible patients are typically excluded from clinical trials, yet they represent the majority of patients that we diagnose and treat—patients with poor performance status and comorbidities,” said invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto....
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
FDA Approves Tremelimumab Plus Durvalumab for Adult Patients With Unresectable HCC
On October 21, the U.S. Food and Drug Administration (FDA) approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial were...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests. The technology, previously tested in animals, was shown to be as...
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression without compromising patients’ quality of life, findings from the randomized phase III NRG...
AI Model Using Daily Step Counts May Help Predict Unplanned Hospitalizations During Cancer Therapy
An artificial intelligence (AI) model developed by researchers may assist in predicting the likelihood that a patient may have an unplanned hospitalization during radiation treatments for cancer. The machine-learning model uses daily step counts as a proxy to monitor patients’ health as they go...
Can Patients With Cancer Treated With Immunotherapy Safely Receive mRNA COVID-19 Vaccines?
New research confirmed the safety of mRNA COVID-19 vaccines in individuals with cancer who are undergoing immunotherapy, according to a novel study published by Widman et al in JNCCN–Journal of the National Comprehensive Cancer Network. The researchers analyzed the frequency of immune-related...
Exercise May Improve Cardiorespiratory Fitness During and After Chemotherapy
During chemotherapy, physical exercise intervention may be safe, improve long-term cardiorespiratory fitness, and alleviate some of the adverse effects of cancer treatment, according to a novel study published by van der Schoot et al in JACC: CardioOncology. The findings suggested that if exercise...
Incidence of Neurologic Side Effects From CAR-T Cell Therapy Is Higher in Patients With Hypophosphatemia, Study Finds
Patients with B-cell malignancies who had hypophosphatemia experienced a higher incidence and severity of neurologic side effects from chimeric antigen receptor (CAR) T-cell therapy, according to a study by Nowicki et al published in Cancer Immunology Research. The study results imply that...
Incidence of Cutaneous Adverse Events With Adjuvant PI3K Inhibitor Therapy
In a systematic review and meta-analysis reported in JAMA Oncology, Jfri et al identified risk for cutaneous adverse events among patients with cancer receiving adjuvant phosphoinositide 3-kinase (PI3K) inhibitor therapy. Study Details The analysis included 15 phase II or III randomized controlled...
Hair-Straightening Chemicals May Be Associated With Higher Uterine Cancer Risk
Individuals who reported using chemical hair-straightening products may be at greater risk for uterine cancer compared to those who did not report using these products, according to a new study published by Chang et al in the Journal of the National Cancer Institute (JNCI). The researchers found no ...
ACS CAN Survey: Female Patients With Cancer Report Less Satisfaction, More Challenges With Cancer Care
Female patients with cancer were less satisfied with the quality of their cancer care than male patients with cancer, according to the results of a survey conducted by the Survivor Views program of the American Cancer Society Cancer Action Network (ACS CAN). In addition, female patients were more...
Maternal Deaths From Cancer Worldwide Have Led to Approximately 1 Million New Maternal Orphans
In 2020, 4.4 million women died from cancer worldwide, leaving behind an estimated 1.04 million maternal orphans (defined as children aged 18 years and younger who have lost their mother), according to the results from a study by Guida et al presented during a press conference at the Union for...
Responses to Irinotecan, Temozolomide, Dinutuximab, and GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma
In a U.S. retrospective study reported in the Journal of Clinical Oncology, Lerman et al found that half of patients with relapsed high-risk neuroblastoma had an objective response to a regimen comprising irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor...
Silicone-Based Polyurethane Film May Reduce Acute Radiation Dermatitis in Patients With Breast Cancer
Mepitel Film—a silicone-based polyurethane film dressing—may be beneficial in reducing skin toxicities caused by radiation treatment, according to data presented during the October 2022 session of the ASCO Plenary Series by Chow et al (Abstract 390226). Results of the phase III trial showed the...
No Benefit for Adjuvant Palbociclib in Stage IIA Breast Cancer: Analysis From the PALLAS Trial
In a preplanned analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with stage IIA breast cancer. Palbociclib offered no additional benefit in terms of invasive disease–free survival (the...
Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening
Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...
Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer
Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...
Researchers Find Possible Link Between Immune Cells’ Closest Neighbors and Survival Time in Patients With Pancreatic Cancer
Researchers have discovered that the organization of different types of immune cells within pancreatic tumors may be associated with how well patients with pancreatic cancer respond to treatment, as well as how long they survive. This information could eventually lead to new ways of treating...
First-Line Nivolumab/Ipilimumab vs Chemotherapy in Metastatic NSCLC Without EGFR or ALK Alterations: 5-Year Survival
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, MSc, FASCO, and colleagues, a 5-year analysis of the phase III CheckMate 227 trial showed improvement in overall survival with first-line nivolumab/ipilimumab vs platinum-doublet chemotherapy, at ≥ 3 years after cessation of...
Prevalence of and Risks for Thoracic Soft-Tissue Sarcomas in Breast Cancer Survivors
In a retrospective cohort study reported in The Lancet Oncology, Veiga et al found that receipt of radiotherapy was the strongest risk factor for development of thoracic soft-tissue sarcomas in U.S. breast cancer survivors; both hypertension and diabetes were significant risk factors for...
Financial Hardship Among Adult Survivors of Childhood Cancer After Implementation of the Affordable Care Act
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Nathan et al found that adult survivors of childhood cancer were more likely to report financial hardship than siblings without cancer in the era following implementation of the Affordable Care...
ASCO Launches Webinar Series to Close the Global Divide Between Survivorship and Palliative Care in Breast Cancer
In honor of Breast Cancer Awareness Month and World Hospice & Palliative Care Day, ASCO and its partners—the International Association for Hospice & Palliative Care; Tómatelo a Pecho, A.C.; the University of Miami Sylvester Comprehensive Cancer Center and Institute for Advanced Study of the ...
David Cescon, MD, PhD, Comments on the MONALEESA Analyses
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
Breast Cancer 2021–2022 Almanac
The past year has seen an unprecedented number of practice-changing advances across all three major breast cancer subtypes. For patients with early-stage triple-negative breast cancer, neoadjuvant chemotherapy plus pembrolizumab firmly entered the standard of care based on improvements in...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Expert Point of View: Patricia LoRusso, DO, PhD
Invited discussant Patricia LoRusso, DO, PhD, of Yale School of Medicine, said to the assembled audience at the 2022 ASCO Annual Meeting: “I see you are as excited about these data as I am,” after the applause ended following Dr. Modi’s presentation. “I want to thank our colleagues for helping to...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...
BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer
Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...
Expert Point of View: Amy Tiersten, MD and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
